Browse drugs

…8 pts allocated 1:1:1 to GUS 400 mg SC every 4 weeks (q4w) (×3)→GUS 200 mg SC q4w (N=140), GUS 400 mg SC q4w (×3)→GUS 100 mg SC eve…

…pleted the DBP, 63 (98.4%) entered the OLE; 22 (100%) continued ELA 120mg treatment, and 20 (95.2%) and 21 (100%) crossed over from…

…on, IFN-γ production, or activation marker expression. In vivo, BLINA monotherapy significantly reduced leukemia burden, but resulted…

…by CTPA in 2/18 (11.1%) with normal or absent D-dimer. Elevated NT-proBNP prompted TTE in 20/31 patients (81%), identifying left ventricu…

…avulanate (n=28; OR 1.04; 95% CI 0.64 to 1.70, where >1 favours amoxicillin-clavulanate). Sixty-three per cent and 29% of amoxicillin and amoxicillin-c…

…ion frequency and mean treatment cost per patient compared with AFLI2, enabling longer treatment intervals through treat-and-extend r…

…umab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent pati…

…nce of females (53.7%). The most commonly used antibiotics were ciprofloxacin (CIP,47.8%), Piperacillin/Tazobactam (PTZ,20.9%), PTZ+Amoxicill…

…uppressants (off-treatment; n = 244), AM monotherapy (n = 198), GC monotherapy (n = 45), or AM and GC combined therapy but no immu…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

… preliminary efficacy, pharmacokinetics and pharmacodynamics of W0180, both as monotherapy and in combination with pembrolizumab (an …

…increased weight (figure 2A, online supplemental table S3). For insulin and ZnT8 autoantibodies, this association was more pronounced i…